← Back to Search

Local Anesthetic

Liposomal bupivacaine for Bunions

Phase 4
Waitlist Available
Led By Elliot Hershman, MD
Research Sponsored by Alexandra Black
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up the study will last 72 hours after the elective procedure.
Awards & highlights

Study Summary

This trial compares two pain relief methods to find which is best for post-op pain management. Pain levels and OMEs used are measured over 72 hrs for comparison.

Eligible Conditions
  • Bunions
  • Liposomal Bupivacaine
  • Postoperative Pain
  • Forefoot Surgery
  • Opioid Use Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~the study will last 72 hours after the elective procedure.
This trial's timeline: 3 weeks for screening, Varies for treatment, and the study will last 72 hours after the elective procedure. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Pain
Secondary outcome measures
Effect of liposomal bupivacaine on opioid use

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Liposomal BupivacaineExperimental Treatment1 Intervention
The liposomal bupivacaine study arm will receive 8cc (13.3 mg/mL) liposomal bupivacaine via intravenous route at the completion of the procedure.
Group II: Bupivacaine HClActive Control1 Intervention
The Bupivacaine HCl study arm will receive 10cc (5mg/mL) of bupivacaine HCl via intravenous route at the completion of the procedure.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bupivacaine
FDA approved

Find a Location

Who is running the clinical trial?

Alexandra BlackLead Sponsor
Elliot Hershman, MDPrincipal InvestigatorNorthwell Health

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~21 spots leftby Apr 2025